RAS:PI3Kα protein-protein interaction

Class

First-in-class RAS:PI3Kα "breaker" (small molecule)

Pathway

Blocks RAS-driven PI3Kα-AKT signaling without inhibiting PI3Kα catalytic activity

Notes

original target text: RAS:PI3Kα protein-protein interaction (covalent Cys242 binder on p110α RBD)

RAS proteins are molecular switches that cycle between inactive and active (GTP-bound) states, and when activated—often by mutation in cancer—they engage multiple downstream signaling pathways to drive uncontrolled cell growth. One of these pathways runs through phosphoinositide 3-kinase alpha (PI3Kα), an enzyme that, once recruited and activated by RAS, generates lipid messengers that activate AKT signaling, promoting cell survival and proliferation. Conventional PI3Kα inhibitors block the enzyme's catalytic site directly, shutting down its activity regardless of what triggered it. Because PI3Kα also participates in normal insulin and growth-factor signaling throughout the body, this broad blockade often causes metabolic side effects, such as elevated blood glucose. An alternative strategy targets the physical contact—the protein-protein interaction—between activated RAS and PI3Kα, rather than the enzyme's catalytic machinery. By selectively disrupting this docking event, a "breaker" molecule can prevent RAS from switching on PI3Kα while leaving the enzyme's intrinsic catalytic capacity, and the signaling it supports in non-RAS-driven contexts, largely undisturbed. This approach is relevant to cancers driven by mutant RAS or by PI3Kα pathway activation, offering a route to interrupt oncogenic signaling with a potentially narrower side-effect profile than pan-catalytic inhibition.